Literature DB >> 23650113

Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.

Vaishali Sanchorawala, Anthony C Shelton, Jerome B Zeldis, David C Seldin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23650113     DOI： 10.1002/ajh.23470

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  3 in total

1.  A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.

Authors:  Ranjit Nair; Shereen Gheith; Dan Popescu; Nicole M Agostino
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 2.  Update on treatment of light chain amyloidosis.

Authors:  Shameem Mahmood; Giovanni Palladini; Vaishali Sanchorawala; Ashutosh Wechalekar
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 3.  Trial Watch: Lenalidomide-based immunochemotherapy.

Authors:  Michaela Semeraro; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.